EP4137138A1 — Methods of treating transthyretin (ttr) mediated amyloidosis
Assigned to Alnylam Pharmaceuticals Inc · Expires 2023-02-22 · 3y expired
What this patent protects
The present invention relates to a transthyretin (TTR)-inhibiting composition for use in reducing a Neuropathy Impairment Score (NIS) or a modified NIS (mNIS+7) or arresting an increase in a NIS or a mNIS+7 in a human subject having a TTR related disorder, wherein the com…
USPTO Abstract
The present invention relates to a transthyretin (TTR)-inhibiting composition for use in reducing a Neuropathy Impairment Score (NIS) or a modified NIS (mNIS+7) or arresting an increase in a NIS or a mNIS+7 in a human subject having a TTR related disorder, wherein the composition is used in an effective amount that reduces a concentration of serum TTR protein to below 50 µg/ml or by at least 80% in the subject.
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.